Dr. McHutchison joined Velia as President and Chief Executive Officer in the first half of 2023. He most recently served as President and Chief Executive Officer at Assembly Biosciences between 2019 through 2022. Prior to this, he was the Chief Scientific Officer and Head of Research and Development at Gilead Sciences. During his ten years at Gilead, he led the organization in the successful filing of numerous New Drug Applications (NDAs) and supplemental label updates across multiple therapeutic areas, including treatments for chronic HBV, and the curative treatment regimens for chronic hepatitis C (HCV) which collectively represent the three most successful drug launches in the pharmaceutical industry. Prior to Gilead, Dr. McHutchison held numerous positions at Duke University Medical Center, including Associate Director of the Duke Clinical Research Institute, Professor of Medicine in the Division of Gastroenterology, Director at Duke Clinical Research Unit, and Co-Director of the Duke Clinical and Translational Science Award. Earlier in his career, Dr. McHutchison spent nearly a decade at Scripps Clinic and Research Foundation and was previously an Assistant Professor of Medicine at the University of Southern California in Los Angeles. Dr. McHutchison received his degrees in medicine and surgery from the University of Melbourne in Australia, completed an internal medicine residency and gastroenterology fellowship at the Royal Melbourne Hospital, and a post-doctoral fellowship in Liver Diseases at the University of Southern California. He is a member of the Royal Australasian College of Physicians, and in 2018, he was appointed an Officer of the Order of Australia(AO).